Fig. 7: FAK inhibition in combination prime line anti-angiogenesis Bevacizumab reduces the tumor growth in MUM 2B xenograft approach. | Cell Death & Disease

Fig. 7: FAK inhibition in combination prime line anti-angiogenesis Bevacizumab reduces the tumor growth in MUM 2B xenograft approach.

From: VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry

Fig. 7

A Tumor growth progression graphic representation on different days, the annotations of the tumor were every two days, being the day 12 post-injection of MUM 2B cells the beginning of different treatments. B Graphic representing final tumor growth with the treatment’s groups (N = 6). C Representative pictures of different tumors from treatment groups.

Back to article page